Novo Nordisk’s Ozempic and Wegovy Prices Slashed 71% Under Medicare Plan
The Centers for Medicare & Medicaid Services (CMS) has negotiated a 71% price reduction on Novo Nordisk’s weight-loss and diabetes drugs Ozempic, Wegovy, and Rybelsus for Medicare enrollees. Effective in 2027, the monthly cost for Ozempic and Wegovy will drop from $959 to $274. The discounts, part of a broader drug pricing deal with the WHITE House, are expected to temper Novo Nordisk’s global sales growth to low-single digits in 2026.
Medicare, the federal health insurance program for seniors and certain disabled individuals, will see significant savings, while Medicaid will extend access to low-income Americans. Novo Nordisk and rival Eli Lilly agreed to the cuts earlier this month, prioritizing broader patient access over short-term revenue. Analysts suggest the move, while impactful, won’t derail long-term growth for the pharmaceutical giant.
